Repros Therapeutics (RPRX) Reports Q2 Loss of $0.18/Share
- S&P, Nasdaq hit highs on gains in health, tech stocks
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
- Broadcom Ltd. (AVGO) Tops Q4 EPS by 11c
- Sibanye Gold (SBGL) to Acquire Stillwater Mining Company (SWC) in $2.2B Deal
- Exclusive: ECB rejects Monte Paschi's request for more time to raise cash - source
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Repros Therapeutics (NASDAQ: RPRX) reported Q2 EPS of ($0.18), versus ($0.32) reported last year.
For earnings history and earnings-related data on Repros Therapeutics (RPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Steelcase (SCS) Reports Preliminary Q3 EPS In-Line with Views, Revs Light
- Lee Enterprises (LEE) Reports Q4 EPS of $0.14
- Finisar (FNSR) Tops Q2 EPS by 12c; Guides Above the Street
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!